Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Bibliographic Details
Main Authors: von Minckwitz, Gunter, Harder, Sebastian, Hövelmann, Sascha, Jäger, Elke, Al-Batran, Salah-Eddin, Loibl, Sibylle, Atmaca, Akin, Cimpoiasu, Christian, Neumann, Antje, Abera, Aklil, Knuth, Alexander, Kaufmann, Manfred, Jäger, Dirk, Maurer, Alexander B, Wels, Winfried S
Format: Online
Language:English
Published: BioMed Central 2005
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242130/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242130/

Similar Items